Search results

The market expects Regeneron (REGN) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2026. This widely-known consensus outlook

The upcoming report from Regeneron (REGN) is expected to reveal quarterly earnings of $8.36 per share, indicating an increase of 1.7% compared to the year-ago period. Analysts forecast revenues of

Regeneron (REGN) came out with quarterly earnings of $9.47 per share, beating the Zacks Consensus Estimate of $8.52 per share. This compares to earnings of $8.22 per share a year ago. These figures

For the quarter ended March 2026, Regeneron (REGN) reported revenue of $3.61 billion, up 19% over the same period last year. EPS came in at $9.47, compared to $8.22 in the year-ago quarter.

The

Regency Centers (REG) came out with quarterly funds from operations (FFO) of $1.2 per share, missing the Zacks Consensus Estimate of $1.21 per share. This compares to FFO of $1.15 per share a year

Regional banks continue to navigate an operating environment shaped by interest rate movements, regulatory oversight and evolving customer expectations. Within this context, Ohio Valley Banc Corp. O

Investors interested in REIT and Equity Trust - Retail stocks are likely familiar with Phillips Edison & Company, Inc. (PECO) and Regency Centers (REG). But which of these two companies is the best

Regional banking institutions continue to operate within an environment shaped by interest rate volatility, regulatory requirements and evolving customer needs. Within this backdrop, Peoples Bancorp

For Immediate Release

Chicago, IL – April 23, 2026 – Today, Zacks Equity Research discussesSimon Property Group SPG, Kimco Realty KIM and Regency Centers REG.

Industry: Retail REITs

Link: https://ww

Sanofi SNY and its partner Regeneron Pharmaceuticals REGN announced that the FDA has approved the expanded use of their blockbuster drug, Dupixent, for the treatment of chronic spontaneous urticaria

In the latest close session, Cisco Systems (CSCO) was down 1.35% at $88.59. The stock fell short of the S&P 500, which registered a loss of 0.41% for the day. On the other hand, the Dow registered a

Regency Centers Corp. REG is slated to report first-quarter 2026 results on April 29, after the closing bell. The company’s quarterly results are likely to display year-over-year growth in revenues

Investors will focus on profits from asthma drug Dupixent and sales of Eylea HD when biotech giant Regeneron Pharmaceuticals, Inc. REGN reports first-quarter 2026 results on April 29, 2026.

The

Regeneron Pharmaceuticals, Inc. REGN reported first-quarter 2026 adjusted earnings per share (EPS) of $9.47, which comfortably beat the Zacks Consensus Estimate of $8.52 and was up from $8.22

Regency Centers Corporation REG reported first-quarter 2026 NAREIT funds from operations (FFO) per share of $1.20, missing the Zacks Consensus Estimate of $1.21 by 0.8%. However, the metric